Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.

Autor: Carrato A; Department of Medical Oncology, Alcalá University, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Ramon y Cajal University Hospital, Madrid.; Pancreatic Cancer Europe, Brussels., Pazo-Cid R; Department of Medical Oncology, Aragon Institute of Biomedical Research, Miguel Servet University Hospital, Zaragoza, Spain., Macarulla T; Vall d'Hebrón Institute of Oncology, Vall d'Hebrón University Hospital, Barcelona., Gallego J; Department of Medical Oncology, Elche University Hospital, Alicante, Spain., Jiménez-Fonseca P; Department of Medical Oncology, Asturias Central University Hospital, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Rivera F; Department of Medical Oncology, Marques de Valdecilla University Hospital, Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain., Cano MT; Department of Medical Oncology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba University, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Reina Sofia University Hospital, Cordoba, Spain., Rodriguez-Garrote M; Department of Medical Oncology, University, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Ramon y Cajal University Hospital, Madrid., Pericay C; Department of Medical Oncology, Sabadell University Hospital, Parc Tauli, Sabadell, Spain., Alés I; Unidad de Gestión Clínica Intercentros (UGCI) Medical Oncology, University Regional and Virgen Victoria Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain., Layos L; Medical Oncology Department, Catalan Institute of Oncology (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol University Hospital, Badalona, Spain., Graña B; Department of Medical Oncology, A Coruña University Hospital, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain., Iranzo V; Department of Medical Oncology, University General Hospital Valencia, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia University, Valencia, Spain., Gallego I; Department of Medical Oncology, Virgen del Rocio University Hospital, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain., Garcia-Carbonero R; Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Universidad Complutense Madrid (UCM), Madrid., de Mena IR; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Madrid., Guillén-Ponce C; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid., Aranda E; Department of Medical Oncology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba University, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Reina Sofia University Hospital, Cordoba, Spain.

Publikováno v: NEJM evidence [NEJM Evid] 2024 Feb; Vol. 3 (2), pp. EVIDoa2300144. Date of Electronic Publication: 2024 Jan 23.

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Autor: Alsina M; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain. malsina@vhio.net., Rivera F; Department of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain., Ramos FJ; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain., Galán M; Department of Medical Oncology, ICO Hospitalet, Avinguda de la Granvia, 199-203, Barcelona, Spain., López R; Medical Oncology Department and Translational Medical Oncology Group, University Clinical Hospital and Health Research Institute (IDIS); CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain., García-Alfonso P; Department of Medical Oncology, H. Gregorio Marañón, Calle del Dr. Esquerdo, 46, Madrid, Spain., Alés-Martinez JE; Department of Medical Oncology, H. Ruber Internacional, Calle de la Masó, 38, Madrid, Spain.; Spain and H Nuestra Sra Sonsoles, C/ Avda. Juan Carlos I, Avila, Spain., Queralt B; Department of Medical Oncology, H. JosepTrueta (ICO), Avinguda de França, Girona, Spain., Antón A; Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, Zaragoza, Spain., Carrato A; Department of Medical Oncology, H. Ramón y Cajal, Ctra. Colmenar Viejo, km. 9, 100 Madrid, Spain., Grávalos C; Department of Medical Oncology, H. 12 de Octubre, Avenida de Córdoba, Madrid, Spain., Méndez-Vidal MJ; Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain., López C; Department of Medical Oncology, H.U. Marqués Valdecilla, Av. Valdecilla, 25 Santander, Spain., de Mena IR; TTD Group, Madrid, Spain., Tabernero J; Vall d'Hebron University Hospital, Department of Medical Oncology, and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain., Giralt J; Department of Radiation Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, Barcelona, Spain., Aranda E; Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, Department of Medical Oncology, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Av. Menendez Pida, Cordoba, Spain.

Publikováno v: Targeted oncology [Target Oncol] 2018 Feb; Vol. 13 (1), pp. 79.